Case Report

Connecting the Dots: Multiple Hemangioblastomas and Pheochromocytoma Revealing the Diagnosis of Von Hippel Lindau Disease

Abstract

Von Hippel–Lindau (VHL) disease is an autosomal dominant hereditary tumor predisposition syndrome caused by pathogenic variants in the VHL gene located on chromosome 3p25.3. It is characterized by the development of multiple benign and malignant neoplasms and cystic lesions involving various organs, with most
manifestations presenting in early to middle adulthood. We report the case of a young female who initially presented with back pain andwas found to have a spinal hemangioblastoma. A concomitant adrenal mass identified incidentally on lumbosacral MRI raised suspicion of an underlying hereditary syndrome.
Subsequent brain MRI demonstrated a fourth ventricular hemangioblastoma. The constellation of multisystem lesions prompted germline genetic testing, which confirmed a pathogenic VHL gene variant, establishing the diagnosis of VHL disease. The coexistence of CNS, spinal, adrenal, renal, or other characteristic tumors should
raise suspicion for VHL syndrome. Diagnosis is established through a combination of clinical evaluation, multimodal imaging, and genetic testing, despite considerable phenotypic heterogeneity.  

[1] Shuin T, Yamasaki I, Tamura K, Okuda H, Furihata M, Ashida S. Von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment. Jpn J Clin Oncol. 2006;36(6):337-43. https://doi.org/10.1093/jjco/hyl052
[2] Lefebvre M, Foulkes WD. Pheochromocytoma and paraganglioma syndromes: genetics and management
update. Curr Oncol. 2014;21(1):8-17. https://doi.org/10.3747/co.21.1579
[3] Maher ER, Yates JR, Harries R, Benjamin C, Harris R, Moore AT, et al. Clinical features and natural history of von HippelLindau disease. Q J Med. 1990;77(283):1151-63. https://doi.org/10.1093/qjmed/77.2.1151
[4] Linehan WM. Molecular targeting of VHL gene pathway in clear cell kidney cancer. J Urol. 2003;170(2 Pt 1):593-4. https://doi.org/10.1097/01.ju.0000077210.05543.ae
[5] Neupane D, Dahal A, Lageju N, Jaiswal LS, Kandel A, Manandhar S. Von Hippel-Lindau disease: a case report. Int J Surg Case Rep. 2022;97:107417. https://doi.org/10.1016/j.ijscr.2022.107417
[6] Kanno H, Kuratsu J, Nishikawa R, Mishima K, Saito N, Nishi T, et al. Clinical features of patients bearing central nervous system hemangioblastoma in von Hippel-Lindau disease. Acta Neurochir (Wien). 2013;155(1):1-7. https://doi.org/10.1007/s00701-012-1514-y
[7] Neumann HP, Eggert HR, Weigel K, Friedburg H, Wiestler OD, Schollmeyer P. Hemangioblastomas of the central nervous system. A 10-year study with special reference to von HippelLindau syndrome. J Neurosurg. 1989;70(1):24-30. https://doi.org/10.3171/jns.1989.70.1.0024
[8] Catapano D, Muscarella LA, Guarnieri V, Zelante L, D’Angelo VA, D’Agruma L. Hemangioblastomas of central
nervous system: molecular genetic analysis and clinical management. Neurosurgery. 2005;56(6):1215-21. https://doi.
org/10.1227/01.NEU.0000159646.15026.D6
[9] Lonser RR, Butman JA, Kiringoda R, Song D, Oldfield EH. Pituitary stalk hemangioblastomas in von Hippel-Lindau
disease. J Neurosurg. 2009;110(2):350-3. https://doi.org/10.3171/2008.4.17532
[10] Wanebo JE, Lonser RR, Glenn GM, Oldfield EH. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg. 2003;98(1):82-94. https://doi.org/10.3171/jns.2003.98.1.0082
[11] Filling-Katz MR, Choyke PL, Patronas NJ, Gorin MB, Barba D, Chang R, et al. Radiologic screening for von Hippel-Lindau disease: the role of Gd-DTPA enhanced MR imaging of the CNS. J Comput Assist Tomogr. 1989;13(5):743-55. https://doi.org/10.1097/00004728-198909000-00001
[12] Filling-Katz MR, Choyke PL, Oldfield E, Charnas L, Patronas NJ, Glenn GM, et al. Central nervous system involvement in Von Hippel-Lindau disease. Neurology. 1991;41(1):41-6. https://doi.org/10.1212/WNL.41.1.41
[13] Opocher G, Conton P, Schiavi F, Macino B, Mantero F. Ph ochromocytoma in von Hippel-Lindau disease and
neurofibromatosis type 1. Fam Cancer. 2005;4(1):13-6. https://doi.org/10.1007/s10689-004-6128-y
[14] Findeis-Hosey JJ, McMahon KQ, Findeis SK. Von Hippel-Lindaudisease. J Pediatr Genet. 2016;5(2):116-23. https://doi.
org/10.1055/s-0036-1579757
[15] Stolle C, Glenn G, Zbar B, Humphrey JS, Choyke P, Walther M, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat. 1998;12(6):417-23. https://doi.org/10.1002/(SICI)1098-
1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K
[16] Brauch H, Kishida T, Glavac D, Chen F, Pausch F, Höfler H, et al. Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum Genet. 1996;95(5):551-6. https://doi.org/10.1007/BF00223868
[17] Dong S, Chu H, Duan R, Bu Y, Jia D, Pan T, et al. Diagnosis and treatment of Von Hippel Lindau syndrome: a case series. Exp Ther Med. 2025;30(3):190. https://doi.org/10.3892/etm.2025.12940
[18] Giles RH, Gläsker S. The first prospective trial for von Hippel- Lindau disease: pazopanib. Lancet Oncol. 2018;19(10):1267-9. https://doi.org/10.1016/S1470-2045(18)30533-3
Files
IssueVol 11 No 4 (2026): July-August QRcode
SectionCase Report(s)
Keywords
Von Hippel Lindau Hemangioblastomas Pheochromocytoma

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Harshitha S, Garg N, Khare J, Suran A. Connecting the Dots: Multiple Hemangioblastomas and Pheochromocytoma Revealing the Diagnosis of Von Hippel Lindau Disease. CRCP. 2026;11(4):190-194.